The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
Cancers · 23.03.2023 · 15 (7) · 1945
DOI: 10.3390/cancers15071945 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.03.2023. Verfasst von Eric J Sohn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH/NCI.
Abstract (Originalsprache)
As detailed by the end replication problem, the linear ends of a cell’s chromosomes, known as telomeres, shorten with each successive round of replication until a cell enters into a state of growth arrest referred to as senescence. To maintain their immortal proliferation capacity, cancer cells must employ a telomere maintenance mechanism, such as telomerase activation or the Alternative Lengthening of Telomeres pathway (ALT). With only 10–15% of cancers utilizing the ALT mechanism, progress towards understanding its molecular components and associated hallmarks has only recently been made. This review analyzes the advances towards understanding the ALT pathway by: (1) detailing the mechanisms associated with engaging the ALT pathway as well as (2) identifying potential therapeutic targets of ALT that may lead to novel cancer therapeutic treatments. Collectively, these studies indicate that the ALT molecular mechanisms involve at least two distinct pathways induced by replication stress and damage at telomeres. We suggest exploiting tumor dependency on ALT is a promising field of study because it suggests new approaches to ALT-specific therapies for cancers with poorer prognosis. While substantial progress has been made in the ALT research field, additional progress will be required to realize these advances into clinical practices to treat ALT cancers and improve patient prognoses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9039, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
ORCID-Profile: Jaewon Min
Förderung
- NCI NIH HHS
- NIH/NCI
Zitieren
APA
Sohn, E. J., Goralsky, J. A., Shay, J. W., & Min, J. (2023). The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT). Cancers, 15(7), 1945. https://doi.org/10.3390/cancers15071945
Vancouver
Sohn EJ, Goralsky JA, Shay JW, Min J. The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT). Cancers. 2023;15(7):1945. doi:10.3390/cancers15071945
BibTeX
@article{Sohn2023,
author = {Sohn, Eric J and Goralsky, Julia A and Shay, Jerry W and Min, Jaewon},
title = {The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)},
journal = {Cancers},
year = {2023},
volume = {15},
number = {7},
pages = {1945},
doi = {10.3390/cancers15071945}
}
EUVIMED